This system treats affected areas of the scalp, requires no manual movement and is the first hands-free Low Level Laser Therapy (LLLT) hair growth device cleared by the FDA for home use. LLLT is rapidly becoming widely accepted as an alternative to drugs and surgery.
"This landmark achievement represents a significant and strategic milestone for Apira Science," said Nicholas Brox, president and CEO, Apira Science. "The platform provides effective LLLT treatment, previously only available in a professional setting. This safe and effective treatment for androgenetic alopecia offers significant advantages over other LLLT devices currently on the market, and will forever change the way men's hair loss is treated. We have invested in innovative engineering and applied science to develop an effective light-based hair growth system that consumers can use in the privacy of their homes."
Male pattern hair loss affects a large portion of the male population according to The International Society of Hair Restoration Surgery. It estimates that that over 35 million men in the US are afflicted with this condition. The onset of male pattern hair loss can begin in the late teen years and progress over a lifetime.
Products that address the in-home device market for LLLT hair growth are expected to grow exponentially through the continued introduction of effective and convenient treatments.
"The platform utilises non-invasive, low-level red laser and LED light to effectively re-energize the unhealthy cells that are in and around the hair follicle," said Jeff Braile, president, medical device division, Apira Science. "We designed this platform to optimise all that is scientifically known about LLLT for hair growth. The results from our recently completed study proved the effectiveness of its LLLT in the treatment of androgenetic alopecia."
For more information, go to www.igrow2laser.com.
